Mednet Logo
HomeRadiation OncologyQuestion

How would you boost a high-risk prostate cancer patient who received standard fractionation treatment and is not able to get LDR boost given COVID-19?

3
3 Answers
Mednet Member
Mednet Member
Radiation Oncology · Virginia Commonwealth University Medical Center

I will assume for the sake of argument that he is also getting ADT as part of his treatment.

If he has responded well to ADT (I like to see about a 90% drop in the PSA within 3 months), my preference would be to try to delay until it's reasonable from an infectious disease perspective to proceed wit...

Register or Sign In to see full answer

Mednet Member
Mednet Member
Radiation Oncology · UPMC Hillman Cancer Center

The question posed is clinically relevant and asks us to weigh the optimal treatment for a high risk patient in the current pandemic setting. I presume the initial course of radiotherapy was standard fractionation of 45 Gy in 25 fractions. Boosting the primary would be standard of care and supported...

Register or Sign In to see full answer

Mednet Member
Mednet Member
Radiation Oncology · CoxHealth Radiation Oncology

We are currently going through extraordinary circumstances which would require unique interventions and approaches.

Most high risk patients prostate cancer patients should already be on androgen deprivation. Hence, delaying the seed implant a few weeks or even months until we address our PPE shortag...

Register or Sign In to see full answer

How would you boost a high-risk prostate cancer patient who received standard fractionation treatment and is not able to get LDR boost given COVID-19? | Mednet